AbbVie to Present Phase 3 Etentamig Results and Data from Broad Multiple Myeloma Portfolio at the 2026 International Myeloma Society (IMS) Meeting
Plenary presentation will feature Phase 3 CERVINO results demonstrating that etentamig met the study's dual primary endpoints of objective response rate (ORR) and progression-free survival (PFS) in relapsed/refractory multiple myeloma (RRMM) Additional presentations highlight research...
Covered in this story
What has happened since
- Provident Financial Services Inc is down 2.7% since this was published, 33 days ago.
- AbbVie is up 9.5% since this was published, 33 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $PFS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Provident Financial Services Inc →Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.